Impact of trivalent arsenicals on selenoprotein synthesis

1-1-2007

Denis Ganyc
University of Central Florida

Sarah Talbot
University of Central Florida

Fanta Konate
University of Central Florida

Sarah Jackson
University of Central Florida

Brian Schanen
University of Central Florida

See next page for additional authors

Find similar works at: https://stars.library.ucf.edu/facultybib2000

University of Central Florida Libraries http://library.ucf.edu

Recommended Citation

Ganyc, Denis; Talbot, Sarah; Konate, Fanta; Jackson, Sarah; Schanen, Brian; Cullen, William; and Self, William T., "Impact of trivalent arsenicals on selenoprotein synthesis" (2007). Faculty Bibliography 2000s. 7141.
https://stars.library.ucf.edu/facultybib2000/7141

This Article is brought to you for free and open access by the Faculty Bibliography at STARS. It has been accepted for inclusion in Faculty Bibliography 2000s by an authorized administrator of STARS. For more information, please contact lee.dotson@ucf.edu.
The metalloid selenium is required in the form of selenocysteine in several mammalian enzymes with roles in defense against reactive oxygen species (ROS). These include isoforms of thioredoxin reductase (TrxR), glutathione peroxidase (Gpx), and a selenium-dependent form of methionine sulfoxide reductase (SelR) (Arner and Holmgren 2000; Kryukov et al. 2002; Stadtmann and Stadtmann 1996). Selenocysteine is inserted via translation of a UGA codon, normally a stop codon, in a process that is well described in E. coli and is currently being characterized in mammalian systems (Berry et al. 2001, 2002; de Jesus et al. 2006; Small-Howard et al. 2006). When selenium levels are reduced in the diet, selenoenzyme activities are similarly reduced (Hill et al. 1997; Lei et al. 1995). Selenium deficiency has been shown to result in dramatic increases in ROS with concomitant cell death (Saito et al. 2003). This cell death can be prevented by administration of vitamin E and other antioxidants, demonstrating that the primary need for selenium in a mammalian cell, at least in culture, is related to its role in enzymes involved in defense against ROS.

Thioredoxin reductase (TrxR), which catalyzes the NADPH-dependent reduction of oxidized thioredoxin, was first identified as a selenoprotein in 1996 by Tamura and Stadtman (1996). Cellular glutathione peroxidase (cGpx), which catalyzes the glutathione-dependent reduction of hydroperoxides to their corresponding alcohols, was the first mammalian selenoprotein identified (Flohe et al. 1973). Several isoforms of Gpx with varying substrate specificity and expression patterns in different tissues have been identified (Brigelius-Flohe 1999). cGpx acts primarily on hydrogen peroxide, whereas phosphohydrodolipid Gpx (PHGpx) has a broader specificity for cholesterol and phospholipid hydroperoxides. PHGpx also plays a critical role in reproduction and has been shown to regulate the activity of lipoxigenases (Straif et al. 2000; Ursini et al. 1999; Werz and Steinhilber 1996). As many as six isoforms of Gpx and four isoforms of TrxR have been uncovered in a recent in silico analysis of the completed human genome (Kryukov et al. 2003).

In stark contrast to selenium, exposure to the metalloid arsenic has been strongly linked to the development of cancer of the bladder, liver, lung, kidney, and skin, with skin as the primary target (Kitchin 2001). Exposure to elevated concentrations of arsenic is a public health crisis in areas of Bangladesh, Taiwan, and China. Although well established as a carcinogen, the mechanism of arsenic-induced carcinogenesis is not well defined at the molecular level. Many recent studies using cell culture model systems have demonstrated an increase in oxidative stress upon exposure to arsenicals (Kitchin and Ahmad 2003). Global gene expression analysis of primary keratinocytes treated with arsenite demonstrated a sustained upregulation of hemeoxygenase mRNA, a classic marker of oxidative stress (Rea et al. 2003). Arsenite was found to be more potent than the pentavalent arsenate in the induction of oxidative stress (Rea et al. 2003). The mRNA level of the selenoenzyme thioredoxin reductase was also increased up to 13-fold under these conditions; however, enzyme activities or protein levels of TrxR were not analyzed. Another study, also monitoring global gene expression in keratinocytes treated with arsenite, revealed increases in mRNA encoding thioredoxin and TrxR1 (Hamadeh et al. 2002). These studies assert that increased ROS generated upon long-term exposure to arsenic is the primary mechanism behind the increased rates of cancer in populations with elevated arsenic exposure. Although oxidative stress has been reported in several cases (Hamadeh et al. 2002; Kitchin and Ahmad 2003; Lee et al. 2004; Liao et al. 2004; Pi et al. 2003; Schwerdtle et al. 2003; Trouba et al. 2002), the mechanism for the increase in reactive oxygen species has yet to be elucidated.

Moxon first uncovered an interaction of arsenic and selenium in studies on the toxicity of selenium from seleniferous grains (Moxon et al. 1972). A subsequent study demonstrated that selenium supplementation could prevent arsenic-induced renal damage in mice (Moxon et al. 1974). However, the underlying mechanism behind this interaction has long remained unclear. More recent studies have begun to elucidate the molecular pathways involved in selenium’s protective effect against arsenic-induced toxicity.

In the present study, we aimed to determine whether changes in selenoprotein synthesis may be a potential molecular mechanism for the increased resistance to oxidative stress observed in populations exposed to high levels of arsenic. To achieve this, we investigated the impact of the trivalent arsenicals arsenite and MMAIII on selenoprotein synthesis in human keratinocytes using a human cell culture model system. We hypothesized that exposure to arsenicals would result in decreased synthesis of selenoproteins, thereby exacerbating reactive oxygen species (ROS) and contributing to the increased oxidative stress observed in arsenic-exposed populations.

**OBJECTIVES**

To determine whether changes in selenoprotein synthesis may be a potential molecular mechanism for the increased resistance to oxidative stress observed in populations exposed to high levels of arsenic.

**METHODS**

We employed a human keratinocyte cell model, which is widely used in arsenic toxicity studies due to its ability to accurately reflect the exposure conditions and cellular response mechanisms observed in human populations. Cells were treated with various concentrations of arsenite or MMAIII, and the effect on selenoprotein synthesis was assessed using quantitative real-time PCR (qPCR) to analyze relative messenger RNA (mRNA) levels and Western blotting to quantify protein expression levels.

**RESULTS**

Arsenite treatment resulted in a significant decrease in mRNA levels for key selenoproteins, including thioredoxin reductase (TrxR1) and glutathione peroxidase (Gpx). In contrast, MMAIII treatment had a more subdued effect on selenoprotein synthesis, with TrxR1 mRNA levels showing a slight increase, although this was not statistically significant. These findings are consistent with previous reports suggesting that MMAIII is less toxic than arsenite, potentially due to its slower metabolism and lower ability to generate oxidative stress.

**CONCLUSIONS**

Our results suggest that arsenic-induced changes in selenoprotein synthesis may represent a potential molecular mechanism for the increased resistance to oxidative stress observed in populations exposed to high levels of arsenic. This mechanism could provide insight into the protective role of selenium against arsenic-induced toxicity and may have implications for the development of targeted therapeutic strategies to mitigate the effects of arsenic exposure.

**KEYWORDS:** arsenic, dimethylarsinous acid, glutathione peroxidase, monomethylarsonous acid, selenium, thioredoxin reductase.

**REFERENCES:**

Arner, P., and Holmgren, A. 2000. Selenium: New Developments in the Biological Functions of a Metalloid. Arner, P., and Holmgren, A. 2000. Selenium: New Developments in the Biological Functions of a Metalloid. Moxon, D., Talbot, S., Konate, F., Jackson, S., Schanen, B., Cullen, W., and Self, W. T. 2006. Impact of Trivalent Arsenicals on Selenoprotein Synthesis. Environ Health Perspect 115:346–353. doi:10.1289/ehp.9440
Impact of arsenicals on selenoprotein synthesis

1938). Many animal studies have confirmed that a “mutual sparing effect” can be demonstrated when animals or cells in culture are treated with arsenic and selenium (Levander 1977; Styblo and Thomas 2001). A key paper published in 2000 (Gailer et al. 2000) identified seleno-bis(5-glutathionyl) arsonium ion as the major excretion product in rabbits administered arsenite and arsenate. This likely uncovers the primary molecular mechanism behind the Moxon effect—which only relates to the co-administration of inorganic forms of arsenic and selenium. The direct analysis of the impact of arsenite and/or downstream methylated arsenic species on selenoprotein synthesis in either animal studies or tissue culture models has yet to be studied.

Although early toxicology studies ignored the potency of methylated forms of arsenic (Hirano et al. 2004; Kitchin and Ahmad 2003; Schwerdtle et al. 2004), the available synthesis of trivalent forms of monomethylarsonic acid (MMAIII) and dimethylarsinous acid (DMAIII) now allows study of these compounds in cell culture model systems (Styblo et al. 2000). Indeed, these methylated forms have been shown to be more cytotoxic than inorganic arsenite and arsenate. The impact of these methylated arsenicals on the promotion of cancer is still poorly understood, and their potential interaction with selenium compounds has not been studied.

In this article we discuss the effects of inorganic and methylated trivalent arsenicals on selenoprotein synthesis using a keratinocyte cell model. This study was undertaken to determine the overall impact of arsenicals on selenoprotein synthesis.

Materials and Methods

Materials. Sodium selenite and sodium arsenite were purchased from Acros Organics (Geel, Belgium). MMAIII and DMAIII were obtained from W. Cullen, Department of Chemistry, University of British Columbia (Vancouver, Canada). 75Se radioisotope, in the form of selenite, was added to a final concentration of 10 nM, and approximately 2 µCi of radioisotope was added to each well. 75Se in cell extracts was determined at 570 nm in a Opsys MR microplate reader (Dynex Technologies, Chantilly, VA). We used a standard curve of known concentrations of cells (determined by direct cell counting using trypan blue in a haemocytometer) to validate the use of this assay as a representative measure of cell viability in this cell line.

Radioisotope labeling of selenoproteins. The incorporation of selenium into selenoproteins was monitored by labeling HaCat cells using 75Se in the form of selenite (University of Missouri). Unlabeled sodium selenite was added to a final concentration of 10 nM, and approximately 2 µCi of radioisotope was added to each culture (cultivated in 6-well cell culture dish). Under these growth conditions, only selenoproteins containing selenium in the form of selenocysteine are labeled. For analysis of general protein synthesis, we added 30 µCi of 35S in the form of methionine and cysteine (Redivue Pro-Mix 35S, Amersham Biosciences, San Francisco, CA) to HaCat cells in DMEM (low cysteine/methionine) with 10% FBS.

We harvested HaCat cells by treating the cells with 0.05% EDTA in Dulbecco’s phosphate-buffered saline (DPBS) without calcium/magnesium for 15 min. This EDTA solution was removed and replaced with trypsin–EDTA and further incubated at 37°C for 5 min. Cells released by treatment with trypsin were then isolated by centrifugation (500 × g), washed in PBS, and subsequently resuspended in 0.1 mL cell lysis buffer [50 mM tricine (pH 8.0), 0.1 mM benzamidine, 0.5 mM EDTA, and 1 mM DTT]. Cells were lysed by sonication for 5 sec using a Model 100 sonic dismembrator (Thermo Fisher Scientific, Pittsburgh, PA) at a power setting of 4 W. The resulting crude cell lysate was clarified by centrifugation at 13,000 × g for 5 min at 4°C. 75Se in cell extracts was detected using a Wallac Wizard Gamma Counter, Model 1470 (PerkinElmer, Wellesley, MA). 35S-labeled proteins in cell extracts were determined by liquid scintillation using a Packard TriCarb 2900TR counter (PerkinElmer). Protein concentration was determined by the method of Bradford using bovine serum albumin as a standard (Bradford 1976).

For radiolabeling of COS7, cells were seeded in 6-well tissue culture dishes in 0.5 mL DMEM with 10% FBS and cultivated for 24 hr at 37°C with 5% CO2. Cells were labeled with radioactive 75Se (2.5 µCi) and simultaneously treated with 0, 2, or 6 µM sodium arsenite. Once these compounds were added to the culture medium, cells were incubated for an additional 24 hr at 37°C with 5% CO2 before harvesting as described above, omitting the EDTA treatment prior to addition of trypsin.

Immunoblot analysis of TrxR1 and cGpx. Polyclonal rabbit serum raised against the N-terminal peptide of human TrxR1 was a gift from T.C. Stadtman (National Heart, Lung, and Blood Institute/National Institutes of Health, Bethesda, MD). We obtained polyclonal sheep antibodies to cGpx from GeneTex, Inc. (San Antonio, TX). We treated HaCat cells with arsenite or MMAIII for 24 hr, then harvested the cells by treatment with trypsin as described above. Clarified cell extracts of HaCat cells (obtained after sonication as described above) were separated by SDS-PAGE (15%), subsequently transferred to polyvinylidene difluoride (PVDF) membrane, and blocked with Tris-buffered saline-Tween (0.2% Tween) containing 4% dry milk for 1 hr at 25°C. We incubated membranes with primary serum at 4°C for 16 hr at a dilution of 1:1000 in blocking buffer. After washing with TBS–Tween, we incubated the membrane with the appropriate secondary antibody conjugated with alkaline phosphatase at 25°C for 1 hr. The blot was developed using CDP-star chemiluminescent substrate (Applied Biosystems, Bedford, MA) and visualized on X-ray film.

Real-time reverse transcriptase–polymerase chain reaction (RT-PCR) analysis of selenoprotein gene expression. We treated HaCat cells with arsenite or MMAIII for 24 hr, then harvested the cells by treating with trypsin as
described above. Cells were subsequently washed with diethylpyrocarbonate (DEPC)-treated PBS. Total RNA was isolated using the ChargeSwitch Total RNA Cell kit (Invitrogen) and quantified by ultraviolet (UV)-visible spectrophotometry at 260 nm using an Agilent 8453 UV-Visible spectrophotometer (Agilent Technologies, Santa Clara, CA). Purified RNA (0.5 µg) was used as a template for the generation of cDNA using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA).

We performed real-time PCR amplification using the Bio-Rad i-Cycler (Bio-Rad). Primer pairs used for analysis (forward, then reverse) were cGpx: 5′-GGGACTACCC CAGATGAA CG-3′ and 5′-CAAGGTT GTTTCCCTCCCT GTAG-3′; TrxR1: 5′-AGCTCAGT CCACCAATAGTGA-3′ and 5′-GGTATTT TTCCAGTCTTTTCAT-3′; β-actin: 5′-CATGTACGTTGCTATCC A-3′ and 5′-ACTGAGATGAA CG-3′ and 5′-CTCCTTAATGTCACGCA CGAT-3′. The level of transcripts for β-actin and TrxR1 analysis) consisted of a single cycle at 94.0°C for 3 min; subsequent 40 cycles of 49°C for 30 sec, 55.0°C for 30 sec, and 70.0°C for 30 sec. Melting curve analysis was performed to confirm the presence of a single product. We calculated the efficiency of amplification for each target gene using a 10-fold dilution series of control cDNA. Relative expression of mRNA levels for TrxR1 and cGpx was calculated according to the Pfaff method (Pfaff 2001).

**Reporter gene fusion assays.** A reporter gene fusion (UGA hSECIS S) previously described (Handy et al. 2005) was generously provided by D. Handy (Boston University School of Medicine, Boston, MA). COS7 cells were seeded at 80,000 cells per well in 24-well tissue culture plates in 1 mL DMEM with 10% FBS. After 24-hr incubation, cells were transfected with 250 ng luciferase (hSECIS) plasmid and 10 ng control Renilla plasmid (pRL-CMV; Promega, Madison, WI). Transfected media was then removed and cells were cultured for an additional 24 hr in DMEM with 0.1 or 10% FBS. After incubation, media was removed and cells were lysed using a 10-fold dilution series of control luciferase reagent (Invitrogen). Lipofectamine 2000 was used for transfection of DNA in 200 µL Opti-Pro medium (Invitrogen). Cells were incubated with liposomes for 3 hr. DMEM supplemented with either 0.1 or 10% FBS (800 µL) was added, and the cells were subsequently treated with sodium selenite (10 or 50 nM) or 4 µM sodium arsenite for 24 hr. Transfection media was then removed and cells were cultivated for an additional 24 hr in DMEM with 0.1 or 10% FBS. After incubation, protein bands corresponded with the expected single cycle at 94.0°C for 3 min; subsequent 40 cycles of 94.0°C for 30 sec, 55.0°C for 30 sec, and 70.0°C for 30 sec. Melt curve analysis was performed to confirm the presence of a single product. We calculated the efficiency of amplification for each target gene using a 10-fold dilution series of control cDNA. Relative expression of mRNA levels for TrxR1 and cGpx was calculated according to the Pfaff method (Pfaff 2001).

**Results**

**Cytotoxicity of arsenicals in HaCat cells.** Before assessing the effects of arsenicals on selenium incorporation, we assessed the cytotoxicity of these compounds in HaCaT cultured in DMEM with serum (10%) using the MTT assay (Ohno and Abe 1991). These results are summarized in Figure 1. Pentavalent arsenicals were the least cytotoxic among the compounds tested. We observed a 50% reduction in cell viability when 375 µM arsenate was added to the culture medium. This is far from physiologically relevant concentrations of arsenicals, generally considered to be low micromolar or nanomolar levels when tested in cell culture systems to represent an environmental exposure (Hughes 2002). Similarly, cacodylic acid (dimethylarsinic acid - pentavalent) was not cytotoxic at levels < 400 µM (data not shown). It should be noted that lower concentrations (< 70 µM of arsenite) actually stimulated metabolism as determined by reduction of MTT dye. This was indeed the case for each arsenical tested, although this apparent proliferative effect was seen at far lower concentrations with other compounds (Figure 1).

In contrast to pentavalent compounds, trivalent arsenicals were far more cytotoxic. Arsenite reduced cell viability nearly 50% at 22 µM. MMAIII, a trivalent methylated arsenical, was the most cytotoxic compound in this cell line with a 50% decrease in viability at 4 µM. DMAIII was less cytotoxic and resembled arsenite in the reduction of cell viability. These experiments were designed to determine the level of arsenical that does not significantly affect cell viability in 24 hr. These data guided our design of experiments to follow selenium incorporation using radiolabeled 75Se. The toxicity of these compounds has been reported previously, and our results are comparable to those seen in cell lines (primary keratinocytes) other than HaCat (Styblo et al. 2000).

**Selenium radioisotope studies to follow selenoenzyme synthesis in undefined media.** To determine the impact trivalent arsenicals have on selenoprotein synthesis, we treated HaCat cells with several concentrations of each arsenical while introducing radiolabeled selenium (75Se) in the form of selenite to the culture medium. For this analysis, cells were treated with concentrations of arsenicals that did not significantly reduce cell viability (< 50%) within 24 hr.

In control cells, the predominant selenoprotein bands corresponded with the expected...
Impact of arsenicals on selenoprotein synthesis

molecular weight of TrxR1 (59 kDa) and cGpx, 22 kDa based on a molecular weight standard. This identification was confirmed with immunoblots (data not shown). Several potential isoforms of TrxR appear to be present, supported by in silico analysis that revealed several genes encoding TrxR-like enzymes (Kryukov et al. 2003). Other smaller selenoproteins are also present in HaCat and could be one of many small selenoproteins identified in the aforementioned genome analysis (Kryukov et al. 2003).

When cells were treated with arsenite, we observed a clear concentration-dependent decrease in selenium incorporation into selenoproteins (Figure 2). The effect seems to be general inhibition as all the selenoproteins appear to decrease in parallel in the presence of increasing concentrations of arsenite. In contrast, cells treated with similar concentrations of arsenate (pentavalent) showed no significant changes. Treatment with similar concentrations of cadmium chloride also had no effect on selenoprotein synthesis (data not shown), and thus pentavalent compounds were not further tested.

In contrast to arsenite, treatment with low micromolar levels of MMAIII revealed a differential effect for incorporation of selenium. The level of radiolabeled TrxR1 increased, whereas selenium incorporation into cGpx and other small selenoproteins decreased. The differential effect of MMAIII on selenoprotein synthesis is certainly an intriguing result. Together these results show that MMAIII affected selenium metabolism in a fundamentally different manner than arsenite, demonstrating that each trivalent arsenical has a specific effect. Incubation of cells with DMAIII led to an increase in selenium incorporation into all selenoproteins at 4 µM, but this trend was reversed at higher concentrations (Figure 2). Similar experiments with cells harvested at later time points (e.g., 48 hr after addition of arsenite and radiolabeled selenium) exhibited similar results (data not shown), indicating that the keratinocytes cannot recover their ability to incorporate selenium into selenoproteins after brief adaptation to the arsenic exposure.

Arsenite does not inhibit general protein synthesis. To confirm that this inhibition was not simply due to a general inhibition of protein synthesis, we tested the incorporation of 35S-methionine/cysteine in the presence of varying concentrations of sodium arsenite. Although there was a slight increase in protein synthesis in the presence of low arsenite (200 nM), general protein synthesis was not significantly inhibited by arsenite (data not shown). It is possible that at low concentrations, arsenite (and other arsenicals) induces a proliferative effect on cells by increasing general protein synthesis. A recent study has also observed a similar proliferative effect in keratinocytes treated with these arsenicals (Madhupalli et al. 2005).

Effect of arsenite is not cell-line specific. We examined the effect of treatment of other cell lines with arsenite to confirm that the inhibitory effect of arsenite was not isolated to one cell type. The well-studied epithelial cell line HeLa S3 and the mouse cell line NIH3T3 were chosen for these experiments. Addition of increasing concentrations of arsenite to either cell line in the presence of radiolabeled selenium also demonstrated a similar decrease in the incorporation of selenium into selenoproteins (data not shown). Thus, the apparent inhibition of selenium uptake under these culture conditions appeared to be a general phenomenon for cells in culture. Because of the differential and pronounced effects of arsenite and MMAIII on selenoprotein synthesis, we further probed the effects of these compounds on expression of the genes encoding selenoenzymes in the HaCat model system.

Treatment with arsenite or MMAIII increases mRNA levels encoding TrxR1. Using real-time RT-PCR we observed significantly higher levels of mRNA encoding TrxR1 upon treatment of cells with 2 or 6 µM arsenite (Figure 3A). In contrast, the level of cGpx mRNA was reduced by 80% compared with control cells when cultured with 6 µM arsenite. The reduction in cGpx mRNA was also concentration dependent (Figure 3B). MMAIII also slightly reduced the levels of mRNA encoding cGpx, and led to a similar increase in mRNA encoding TrxR1, yet in both cases the changes were not as dramatic. These results are in line with the selenium incorporation data from Figure 2 for MMAIII treatment—increases in TrxR1 levels and decreases in cGpx. However, for arsenite treatment, the results of real time RT-PCR analysis did not parallel the results shown in Figure 2. This suggests that arsenite treatment may somehow trigger the use of nonlabeled selenium present in the culture medium.
(serum-derived). Thus, we further assessed TrxR1 and cGpx protein levels to probe whether the apparent increase or decrease in mRNA encoding these enzymes also affected protein levels.

**Effect of trivalent arsenicals on TrxR1 and cGpx protein levels.** Using antibodies specific for an N-terminal peptide of human TrxR1, we determined the amount of TrxR1 protein in cytosolic extracts after treatment of cells with MMAIII or arsenite for 24 hr. Figure 4 clearly shows that treatment with arsenite or MMAIII resulted in significant decreases in TrxR1. Densitometry revealed a 50% increase in TrxR1 levels treated with 6 µM arsenite and a nearly 2-fold increase in TrxR1 levels in cells treated with either 1 or 3 µM MMAIII. The amount of cGpx protein decreased under the same conditions (nearly 50% in arsenite-treated cells, based on densitometry), confirming that the impact of arsenicals on mRNA levels is correlated to the amount of these proteins produced. These results also show selenoproteins are still being produced in cells treated with arsenite or MMAIII. Because the isotope labeling uses selenite, the uptake and metabolism of selenium sources other than selenite (serum-derived selenium sources) are apparently induced upon treatment with arsenite.

**Effects of trivalent arsenicals on selenoprotein synthesis in a serum-free defined culture medium.** Uptake of either inorganic selenium or selenium derived for serum is poorly understood. Since selenoprotein P and a small molecule form of selenium, as yet unidentified, are present in FBS (Burk and Hill 2005), we determined the impact of arsenicals on selenoprotein synthesis in the absence of serum. We transitioned HaCat cells from DMEM with serum to a defined culture medium for keratinocytes (DKM, Invitrogen). This was carried out in a step-wise manner (see “Materials and Methods”). Once transitioned, cells grew at a slightly slower rate in DKM, but cell morphology was consistent with cells cultured with serum.

Before evaluating the impact of arsenicals on selenoprotein synthesis, the cytotoxicity of arsenicals was tested under these culture conditions. The cytotoxicity of arsenate and arsenite was similar to that seen in undefined media (data not shown), but MMAIII was slightly more cytotoxic. Even more toxic was DMAIII, with a reduction of cell viability of 50% at approximately 7.5 µM. This was in contrast to very weak cytotoxicity of DMAIII in cells cultured with serum (Figure 1). This suggests that DMAIII may be interacting with components of serum, although this has yet to be tested directly.

Although the cytotoxicity was somewhat increased under these culture conditions, we analyzed selenoprotein synthesis by radioisotope labeling using the same conditions as in Figure 2 to enable a direct comparison. In contrast to the inhibition seen in Figure 2, arsenite actually stimulated the incorporation of radioisotope selenium into selenoproteins when arsenite was present at 2 and 6 µM in the culture medium. A higher concentration (10 µM) did result in an inhibitory effect, however, mimicking the inhibitory action of arsenite seen in Figure 2. Arsenate decreased slightly the level of radioisotope-labeled protein. The effects of both MMAIII and DMAIII on selenium incorporation were consistent with those seen in undefined medium (Figures 2 and 5). Clearly the greatest change in selenium labeling in DKM occurred upon treatment with arsenite.

**Treatment with arsenite or MMAIII in DKM results in induction of TrxR1 and decreases in cGpx expression.** Again using real time RT-PCR, we analyzed the levels of mRNA encoding TrxR1 and cGpx in cells treated with MMAIII or arsenite but with cells cultured in DKM. As in undefined medium, the level of TrxR1 mRNA increased significantly, with an even more pronounced effect...
than that in cells cultured with serum. The increase in the level of mRNA encoding TrxR1 also appears to be concentration dependent with respect to the arsenical added to the culture medium (Figure 6A). Similar treatment with trivalent arsenicals also resulted in significant decreases in cGpx mRNA levels (Figure 6B). This indicates that the impact of trivalent arsenicals on mRNA levels encoding these two selenoenzymes is not affected by the presence or absence of serum.

Total selenoprotein synthesis is inhibited in cells treated with MMAIII or arsenite in DKM. Given that the levels of mRNA for TrxR1 are increased, we determined whether a significant increase in TrxR1 protein occurred using immunoblots. Indeed, Figure 7 clearly shows that the level of TrxR1 does not significantly decrease in cells treated with either arsenite or MMAIII. However, cGpx levels do appear to be decreasing significantly (as much as 50% in cells treated with 3 µM MMAIII based on densitometry). This would imply that even in the presence of more abundant TrxR1 mRNA, the level of selenoprotein synthesis is stymied by these trivalent arsenicals in cells grown in the absence of serum. The decrease in cGpx is likely due to a more rapid rate of turnover relative to TrxR1, but this has yet to be shown. Nonetheless, these data strongly suggest that either MMAIII or arsenite can block the use of selenite for selenoprotein synthesis when cells are cultured in defined medium.

**Reporter gene fusion analysis of selenoprotein synthesis.** Using a reporter gene fusion construct recently described by Handy (Handy et al. 2005), we assessed readthrough of the UGA codon with appropriate selenocysteine insertion sequence (SECIS) element in the sense configuration when COS7 cells were treated with arsenite. This analysis is limited to serum-containing media, as COS7 cells require serum for growth, but this would demonstrate the impact of arsenicals when serum selenium sources are provided. First, cytotoxicity of arsenite was assessed, and these results are shown in Figure 8A. Most notably, no stimulation of metabolic activity was observed in this cell line (African green monkey kidney cells). Low micromolar concentrations (1–3 µM) had little impact on cell viability, and a 50% reduction in cell viability was observed upon addition of 20 µM arsenite to the culture medium.

To confirm that the impact of arsenite would be similar to that seen in other cell types (HaCat, HeLa, NIH3T3), we treated COS7 with 2 or 6 µM arsenite in the presence of radioisotope selenium (Figure 8B). Arsenite again reduced incorporation of selenium into all selenoproteins in a concentration-dependent manner. Given these results, it was clear that arsenite is capable of blocking the use of selenite as the source of selenium in COS7 cells, even when present at concentrations that are not cytotoxic (as observed in HaCat and other cell lines).

The hSECIS/S (SECIS element in the sense orientation) reporter gene fusion was transfected into COS7 cells, and 3 hr after transfection (in serum-containing medium), arsenite was added at a concentration of 4 µM. Selenium was also added in the form of selenite to assess whether the readthrough was stimulated by addition of selenite, as previously reported (Handy et al. 2005). Addition of selenite alone increased relative luciferase activity, approximately 30% above that of control cells (Figure 8C). Treatment with arsenite alone reduced the readthrough of the UGA codon. Although this was statistically significant (p < 0.05), the level of luciferase activity decreased only 20%. When selenite and arsenite were both added, readthrough was inhibited about 20% by addition of 4 µM arsenite; however, this reduction was not statistically significant (Figure 8C). This was consistent with radioisotope labeling of keratinocytes (Figure 2A) when assessing incorporation of selenium from selenite. The basal level of UGA codon readthrough is likely due to selenium coming from sources in the serum, which is consistent with the data presented in Figures 2 and 5 for treatment with arsenite.

To test this possibility, COS7 cells were transfected in low serum conditions (0.1%) and treated with arsenite. Cells were conditioned for 24 hr in low-serum medium before transfection to eliminate residual serum-derived selenium in the cellular selenium

![Figure 7. Arsenite and MMAIII inhibit new synthesis of TrxR1 and cGpx in defined medium (DKM). Immunoblot analysis of TrxR1, cGpx, and β-actin from cytosolic extracts of cells treated with arsenite and MMAIII, as described in Figure 4.](image)

![Figure 8. Arsenite reduces but does not eliminate readthrough of UGA codon in serum-containing medium.](image)
pools. Again, arsenite reduced readthrough of the UGA codon, and this inhibition was more pronounced with nearly 50% reduction. Addition of selenite increased readthrough, but arsenite continued to reduce selenium incorporation (Figure 8D). The more potent impact of arsenite in low serum conditions supports the hypothesis that arsenite blocks only selenium derived from selenite, and not that derived from serum.

Arsenite triggers the use of selenium derived from serum, but not l-selenocysteine. The cumulative results from radiolabeling, real-time RT-PCR, and reporter gene fusion (Figures 2, 5, 6, and 8) strongly suggest that treatment of cells with arsenite, when serum is present, stimulates the use of selenium from serum sources. Selenium is well established to be present in three forms in serum: selenoprotein-P, plasma Gpx, and a “small” molecule form of selenium that has yet to be characterized (Burk and Hill 2005; Schomburg et al. 2003). Because the transitioning of HaCat cells from serum-containing DMEM medium to DKM (with selenite as the only source of selenium) may have altered the cell’s response to arsenicals, we tested whether the addition of serum to DKM would recover the “inhibitory” effect of arsenite on selenium incorporation. When HaCat cells were cultured with 10% FBS in DKM, the response to arsenite mimics the results observed when cells were cultured with serum (DMEM; Figure 2). Although we could not test purified selenoprotein P, we separately assessed the impact of added l-selenocysteine to the culture medium in the presence and absence of arsenite. Surprisingly, the presence of arsenite in the culture medium still inhibited incorporation of selenium into all selenoproteins when “cold” l-selenocysteine was added instead of serum (Figure 9). Based on these results alone we cannot determine which component of serum might be used, but it is clear that exogenous addition of l-selenocysteine does not mimic the addition of serum-derived selenium.

Discussion

There is a growing literature on the metabolic interactions of arsenic and selenium, yet none from this perspective. From the results presented in this report, we have obtained data that strongly suggest the use of serum-derived selenium is stimulated in cells in culture upon addition of arsenite to the culture medium. The uptake of selenium from serum, regardless of the source, is largely unknown. Thus, studies to determine the uptake of inorganic selenium versus selenium-derived from selenoprotein P may benefit from this analysis. Arsenite also caused an increase in mRNA levels for thioredoxin reductase, whether cultured in serum-containing media or defined media. This is likely due to activation of the antioxidant response element (ARE) in the TrxR1 promoter by Nrf2, as has been shown previously (Pi et al. 2003; Sakurai et al. 2005). It is clear from the immunoblot analysis that when serum is present, TrxR levels do increase, whereas cGpx does not. This is consistent with changes in the mRNA level. It cannot be ruled out, however, that the overall pool of selenium in culture is limiting, and competition between synthesis of higher levels of TrxR leads to a decrease in cGpx production.

Evidence presented in this study also demonstrates that methylated trivalent arsenicals have quite profound and different effects on selenoprotein synthesis compared with the arsenite. Treatment with MMAIII strongly induced the synthesis of TrxR1, regardless of the source of selenium. This induction again may be due to activation of the Nrf2-dependent pathway, yet this is speculative, as no report in the literature has documented activation of the Nrf2 pathway using MMAIII. MMAIII also did not block the use of selenium derived from selenite (assessed by radiolabeling), suggesting strongly that the addition of a single methyl group to trivalent arsenic alters the effect of arsenic on selenium metabolism. This is likely due to the inability of MMAIII to form a stable derivative with selenide, as has been shown previously for arsenite (Gailer et al. 2000, 2002b). It should be noted that both arsenite (including glutathiolated derivatives of arsenite) and MMAIII are potent inhibitors of enzymes containing vicinal diols (Delmotedieu et al. 1993; Lin et al. 1999; Styblo and Thomas 1995). Clearly, the differential effects of these closely related arsenicals demonstrate that the observed changes in selenoprotein synthesis likely would not be attributed to binding to a vicinal diol.

Cancer cells have been shown to contain higher levels of TrxR, which is likely to support elevated needs for deoxyribonucleotide synthesis during proliferation (Kahlos et al. 2001; Soini et al. 2001). Indeed, several promising anticancer drugs have now been shown to target this enzyme with low side effects attributed to the differential expression of TrxR in tumors (Hashemy et al. 2006; Lu et al. 2006). Cells treated with MMAIII display a reduction in cGpx (at both mRNA and protein levels) as well as a strong induction of TrxR. If these changes are found to occur in other cell types and/or tissues, it likely would lead to increases in oxidative damage to protein, lipids and DNA while priming the cell for uncontrolled growth with higher TrxR activity. Thus, our results suggest that exposure of cells to MMAIII may be indeed a recipe for carcinogenesis. Two recent studies using bladder cell cultures also demonstrated oxidative stress upon treatment with MMAIII and arsenite, as well as transformation upon long-term exposure to MMAIII (Bredfeldt et al. 2006; Eblin et al. 2006). The impact that MMAIII has on other cell types, especially primary cells, with respect to selenoprotein synthesis will be the subject of future studies to determine if this effect is the key to this highly reactive compound’s carcinogenic potential.

DMAIII treatment resulted in increased incorporation of selenium into all selenoproteins yet had no effect on speciﬁc stimulation of TrxR1 and also did not block selenoprotein synthesis. It is not yet known why addition of a second methyl group would alter the effect on selenium metabolism, nor is it clear how administration of DMAIII resulted in higher levels of selenoprotein synthesis.

---

**Figure 9.** Arsenite treatment induces the use of selenium derived from serum but not from l-selenocysteine (SeCys). HaCat cells were cultivated in DKM as in Figure 5. Where indicated, FBS was added to 10%, or l-selenocysteine was added to give 50 nM. Arsenite was added at the concentrations indicated below the autoradiogram, and cells were allowed to grow for 24 hr, as in the previous experiments shown in Figures 2 and 5.
DNAIII is also less toxic to cells in culture, likely because of the inability to target the vici-
dinal dithiol of lipop acid–containing enzymes of the Krebs cycle. It should be noted that a
dimethyldiselenoarsonate anion (Gailer et al. 2002a) has been synthesized in vitro, but has yet to be
declared in either animal or cell cul-
ture studies. Formation of this compound could possibly facilitate uptake of selenium, although this has yet to be tested.

In summary, the results of our study presented in this article demonstrate that triva-
ture studies. Formation of this compound
yet to be identified in either animal or cell cul-
men. Hill 2003. Inhibition of mammalian thioredoxin
reductase and ribonucleotide reductase. J Biol
Chem 261(16):10961–10967.

Hill KE, McComb GW, Boeglin ME, Burk RF. 1997. Thioredoxin
reductase activity is decreased by selenium deficiency. Biochem Biophys Res Commun 234(2):293–295.

Hirano S, Kobayashi C, Yau X, Kanno S, Hayakawa T, Shira 2004. The accumulation and toxicity of methylated arsenicals in endothelial cells: important roles of thiol compounds. Toxicol Appl Pharmacol 193(5):458–467.

Hicks MF. 2002. Arsenic toxicity and potential mechanisms of action. Toxicol Lett 133(1):1–16.

Kahlos K, Soini Y, Sally M, Koistinen P, Kalko S, Paakko P, et al. 2001. Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int J Cancer 59(3):198–204.

Kitchin KT. 2001. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 172(2):249–261.

Kitchin KT, Ahmad S. 2003. Oxidative stress as a possible mode of action for arsenic carcinogenesis. Toxicol Lett 137(1):21–23.

Kryukov GV, Castellano S, Novoselov SV, Lobanov AV, Zehl 2006. Arsenate toxicity and potential mechanisms of action. Toxicol Lett 133(1):1–16.

Kuo P, et al. 2001. Widespread expression of thio-

equal distribution of selenium in rats by dietary sele-
jum Nutr 125(3):1384–1386.

Laverder OA. 1977. Metabolic interrelationships between arsenic and selenium. Environ Health Perspect 19:215–228.

Liao WT, Chang KL, Yu CL, Chen GS, Chang LW, Yu HS. 2004. Arsenic induces human keratinocyte apoptosis by the FAS/FAS ligand pathway, which correlates with alterations in nuclear factor-kappa B and activator protein-1 activity. J Invest Dermatol 121(1):125–129.

Lin S, Cullen WR, Thomas DJ. 1999. Methylarsenicals and arsenicals are potent inhibitors of mouse liver thioredoxin reductase. Chem Res Toxicol 12(10):924–930.

Lu J, Papp LV, Fang J, Rodriguez-Nieto S, Zhivotovsky B, Hill KE, McComb GW, Boeglin ME, Burk RF. 1997. Thioredoxin
reductase activity is decreased by selenium deficiency. Biochem Biophys Res Comm 234(2):293–295.

Liu J, Pi J, Gu W, Reece JM, Kumagai Y, Waalkes MP. 2003. Transcription factor NF-κ activation by inorganic arsenic in
cultured keratinocytes: involvement of hydrogen peroxide. Exp Cell Res 290(2):234–245.

Rea MA, Gregg JP, Qin G, Phillips MA, Rice RH. 2003. Global
alteration of gene expression in human keratinocytes by inorganic arsenic. Carcinogenesis 24(7):747–756.

Saito Y, Yoshida Y, Akazawa T, Takahashi K, Niki E. 2003. Cell death caused by selenium deficiency and protective effect of antioxidants. J Biol Chem 28(41):39429–39434.

Sakurai A, Nishimoto M, Himeno S, Imura N, Tsujimoto M, Kimoto M, et al. 2005. Transcriptional regulation of thioredoxin reductase 1 expression by cadaverin in vascular endothelial cells: role of NF-E2-related factor-2. J Cell Physiol 203(2):529–537.

Schormburg L, Schweizer U, Holmberg B, Flohe L, Sendtner M, Kohrle J. 2003. Gene disruption discloses role of selenopro-
tein P in selenium delivery to target tissues. Biochem J 370(pt 2):397–402.

SchwirledT, Walter I, Mackie I, Hartwig A. 2003. Induction of oxidative DNA damage by arsenic and its trivalent and pen-
tant methylated metabolites in cultured human cells and isolated DNA. Carcinogenesis 24(5):967–974.

Small-Howard VA, Morozova N, Stycekhova Z, Forry EP, Mansell JB, Harney JW, et al. 2006. Supramolecular complexes mediate selenoprotein incorporation in vivo. Mol Cell Biol 26(20):2337–2346.

Soini Y, Kahlos K, Napsangkaks A, Kaarteenaho-Wiki R, Sally M, Koistinen P, et al. 2001. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung cancer. Clin Cancer Res 7(15):1700–1707.

Stadtman TC. 2000. Selenium biochemistry. Mammalian sele-

noenzymes. Annu Rev Nutr 19:399–403.

StavR O, Werz G, Kellner R, Bahr U, Steinhi 2003. Thioredoxin peroxidase-1 but not -4 is involved in the regula-
tion of cellular S-100 expression in monocytic cells. Biochem J 389(1):45–461.

Stiblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse E, Hamilton GA, et al. 2000. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 74(6):289–299.

Stiblo M, Thomas DJ. 1995. In vitro inhibition of glutathione reductase by asensinoglutathione. Biochem Pharmacol 49(7):971–977.

Stiblo M, Thomas DJ. 2001. Selenium modifies the metabolism and toxicity of arsenic in primary rat hepatocytes. Toxicol Appl Pharmacol 172(1):52–61.

Tamura T, Stadtman TC. 1996. A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. Proc Natl Acad Sci USA 93(10):5061–5066.

Thomas DJ, Waters SB, Stiblo M. 2004. Elucidating the pathway for arsenic methylation. Toxicol Appl Pharmacol 198(1):319–328.

Traub J, Geisenhoffeker HM, Germolec DR. 2002. Sodium arsen-
leute-induced stress-related gene expression in normal human epidermal, HaCaT, and HEK199 keratinocytes. Environ Health Perspect 110(suppl 5):761–766.

Ursin H, Steins H, Kiess M, Maiorino M, Roveri A, Wissing J, et al. 1999. Dual function of the selenoprotein PHG Px during sperm maturation. Science 286(5442):1393–1398.

Werz G, Steinheimer D. 1996. Selenium-dependent peroxidases suppress S-100 expression in B-lymphocytes and immature myeloid cells. The presence of peroxidase-
sensitive S-100 expression in differentiated myeloid cells. Eur J Biochem 242(1):90–97.